$CV News
Last published 4h ago
- 4h agoCVCapsoVision, Inc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoCVCapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026GlobeNewswireSARATOGA, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced
- 1mo agoCVCapsoVision to Present at the 20th Annual LD Micro Main EventGlobeNewswireSARATOGA, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced
- 2mo agoCVCapsoVision to Participate in Upcoming Investor ConferencesGlobeNewswireSARATOGA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced
- 3mo agoCVCapsoVision Reports Second Quarter 2026 Financial ResultsGlobeNewswireSARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported
- 3mo agoCVCapsoVision® Announces International Launch of AI HighlightsGlobeNewswireSARATOGA, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced
- 3mo agoCVCapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026GlobeNewswireSARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced
- 4mo agoCVCapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of DirectorsGlobeNewswireSARATOGA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, announced the
- 6mo agoCVCapsoVision Reports First Quarter 2026 Financial ResultsGlobeNewswireSARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported
- 6mo agoCVCapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026GlobeNewswireSARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced
- 7mo agoCVCapsoVision Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireSARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported
- 8mo agoCVCapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026GlobeNewswireSARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced
- 8mo agoCVCapsoVision to Participate in the 38th Annual ROTH ConferenceGlobeNewswire- Company to participate in a fireside chat and 1x1 investor meetings on March 23, 2026 - SARATOGA, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology
- 10mo agoCVCapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®GlobeNewswireSARATOGA, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced
- 11mo agoCVCapsoVision to Participate in the Benchmark 14th Annual Discovery Investor ConferenceGlobeNewswireSARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced
- 12mo agoCVCapsoVision Reports Third Quarter 2025 Financial ResultsGlobeNewswireSARATOGA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported
- 1y agoCVCapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening CapsuleGlobeNewswireSARATOGA, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced
- 1y agoCVCapsoVision Appoints David Garcia as Senior Vice President of FinanceGlobeNewswireSARATOGA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced
- 1y agoCVCapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025GlobeNewswireSARATOGA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced
- 1y agoCVCapsoVision to Participate in the 4th Annual ROTH Healthcare Opportunities ConferenceGlobeNewswireSARATOGA, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc.
- 1y agoCVCapsoVision Reports Second Quarter 2025 Financial ResultsGlobeNewswireSARATOGA, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported
- 1y agoCVCapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025GlobeNewswire- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company that
- 1y agoCVCapsoVision Announces Closing of Initial Public OfferingGlobeNewswireSARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence ("AI") technologies that are
- 1y agoCVCapsoVision Announces Pricing of Initial Public OfferingGlobeNewswireSARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence ("AI") technologies that are
- 5y agoCLIIGIBHERUN+2Sunrun Announces Co-Founder and CEO Lynn Jurich to Transition to Executive Co-Chair of the Board; Mary Powell to Become Company's Next CEOGlobeNewswireSAN FRANCISCO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Sunrun Inc. (NASDAQ:RUN), the nation's leading provider of residential solar, storage and energy services, today announced that Mary Powell, a Sunrun Director and former President and CEO of Green Mounta
- 15y agoCVFaruqi & Faruqi, LLP Announces Investigation of Central Vermont Service Corp.Business WireNEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Central Vermont Public Service Corp. (“Central Vermont” or the “Company”) (NYSE: CV) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Fortis Inc. in a deal valued at about $654 ...
- 15y agoCVKendall Law Group Investigates Central Vermont Public Service AcquisitionBusiness WireDALLAS--(BUSINESS WIRE)--Kendall Law Group, led by former federal judge Joe Kendall, is investigating Central Vermont Public Service (NYSE: CV) for shareholders in connection with the proposed acquisition by Fortis Inc. The national securities firm’s investigation seeks to determine whether Central Vermont and its Board breached their fiduciary duties by entering into the agreement without properl ...
- 15y agoCVHarwood Feffer LLP Announces Investigation of Central Vermont Public Service Corp.Business WireNEW YORK--(BUSINESS WIRE)--Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Central Vermont Public Service Corp. ("Central Vermont" or the "Company") (NYSE: CV) concerning Fortis Inc.’s proposed offer to purchase the Company for $35.10 per share in a transaction valued at approximately $700 million.
- 15y agoCVRobbins Umeda LLP Is Investigating Central Vermont Public Service for ShareholdersBusiness WireSAN DIEGO--(BUSINESS WIRE)--Robbins Umeda LLP, a shareholder rights litigation firm, is interested in helping shareholders of Central Vermont Public Service (NYSE:CV). The firm has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the board of directors of Central Vermont in connection with their efforts to sell the company to Forti ...
- 15y agoCVThe Briscoe Law Firm Announces Investigation of Central Vermont Public Service (CV)Business WireDALLAS--(BUSINESS WIRE)--The Briscoe Law Firm, PLLC, founded by a former state prosecutor and enforcement attorney for the United States Securities and Exchange Commission, and the securities litigation law firm of Powers Taylor, LLP are investigating potential legal claims against the Board of Directors of Central Vermont Public Service (“CV” or “Central Vermont Public Service”) (NYSE: CV) relate ...
- 15y agoCVMurray, Frank & Sailer LLP Announces Investigation of the Acquisition of Central Vermont Public Service Corp.Business WireNEW YORK--(BUSINESS WIRE)--Murray, Frank & Sailer LLP is investigating claims of breach of fiduciary duty by certain members of the board of directors of Central Vermont Public Service Corp. (NYSE: CV) (“Central Vermont” or the “Company”) in relation to the acquisition of the Company by Fortis Inc. (“Fortis”).